Navigation Links
Nouveau Life Pharmaceuticals (NOUV) to Begin Sales of Azul Instant™
Date:6/6/2012

FORT LAUDERDALE, Fla., June 6, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals Inc. (Pink Sheets: NOUV), a provider of quality all-natural dietary supplements, reported today that production is complete on the first run of Azul Instant™, an all-natural male enhancement supplement for erectile dysfunction (ED) that works in 5 minutes and lasts up to 48 hours.

Nouveau Life began production of Azul Instant™ earlier this spring. Manufacturing is complete, and the product is currently being shipped to the warehouse. Nouveau Life anticipates online sales of Azul Instant™ to begin in the next two weeks.

In addition, Nouveau Life has released a complementary product to Azul Instant™ that can be taken daily to help the over 30 million men in the U.S. who suffer with ED. The new supplement Azul: Male Enhancer™ is designed to support a healthy libido in men. Regular use of the supplement Azul: Male Enhancer™ promotes being ready when it counts. Azul: Male Enhancer™ is available for purchase at www.nlpnaturals.com.

"It made sense to us that some men would prefer a daily supplement while some men would prefer a supplement that could be taken only when needed," stated Nouveau Life CEO Melissa Walker. "We are working behind the scenes to get Azul Instant™ on the market as quickly as possible. We know the market has been anxious for the supplement's arrival, as have we. It is the only all-natural ED supplement on the market that works in 5 minutes. In the meantime, we're proud to announce our daily ED supplement Azul: Male Enhancer."

With the addition of Azul: Male Enhancer™, Nouveau Life currently offers three all-natural supplement products. Nouveau Life's signature New Life Naturals™ line includes New Life Naturals: For Her Senses™ intended to help the nearly 48% of American women suffering with female sexual dysfunction (FSD) and New Life Naturals: For Your Weight Loss™, a Raspberry Ketone Formula with Acai designed to aid in safe weight loss for the 36% of Americans classified as obese. All of Nouveau Life's products can be purchased by visiting www.nlpnaturals.com.

About Nouveau Life Pharmaceuticals
The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.

CONTACT:
Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
2. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... The global wound care market ... at a CAGR of 6.7% during 2016-2022 Among the various ... largest share in the global market in 2015. Among the various applications, ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... ... Research, a leading publisher of cannabis market research, the legal ... 27 percent CAGR through 2021, despite conflicting signals from the ... Analytics, points out that the two biggest drivers of growth ...
(Date:3/24/2017)... Global Ampoules Market report provides ... applications and industry chain structure. The Ampoules market analysis ... competitive landscape analysis, and major regions, development status. ... ... providing 10 company profiles and 183 tables and figures ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health ... there could be four million Zika-related cases in the Americas within the next year. ... US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... Minneapolis, MN (PRWEB) , ... March 23, 2017 , ... ... with internet and WiFi connectivity are making a huge impact on businesses and individual ... Global Institute estimates the IoT will have a value anywhere from $4 trillion to ...
(Date:3/23/2017)... ... March 23, 2017 , ... Dilger-Maxwell ... of the Norwalk and Vermillion areas, celebrates the newest charity campaign in ... nonprofit, community-based substance abuse prevention and peer recovery support organization providing vital ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
Breaking Medicine News(10 mins):